Earlier LPA1 antagonist failures (2010s)
Bristol Myers scrapped an earlier LPA1 antagonist because of liver toxicity in clinical testing. Amgen also canceled its LPA1 drug after it fell short in a Phase 2 trial.
The failures left the LPA1 class unproven and raised the bar for any new drug in the class.
Admilparant became the first LPA1 antagonist to reach Phase 3 testing, carrying the class's hopes.
Admilparant is the first LPA1 antagonist to succeed in a Phase 3 trial, but the liver safety concerns that sank earlier drugs in the class still hang over it.
